WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and ...
Incyte Corporation INCY recently announced positive top-line results from the late-stage TRuE-AD3 study on Opzelura (ruxolitinib cream). TRuE-AD3 (NCT04921969) is a randomized, double-blind, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果